Skip to content

Study · Animal study (in vivo) · dog · 1985

13 results

Dose-response studies on male reproductive parameters in dogs with nafarelin acetate, a potent LHRH agonist.

Vickery BH, McRae GI, Briones WV, Roberts BB, Worden AC, Schanbacher BD, Falvo RE

Journal of andrology1 Jan 1985Cited by 20 (Europe PMC)

PMID3156111 (opens in a new tab)DOI10.1002/j.1939-4640.1985.tb00815.x (opens in a new tab)PepBankPUB-03156111
Source linkPubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, early nafarelin injections raised circulating gonadotropins.

    In plain wordsIn dogs, early nafarelin injections raised circulating gonadotropins.

    Peptide
    Nafarelin
    Outcome
    IncreaseEarly gonadotropin response
    Study

    dogn: not reported in source

    adult male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 or 2.0 micrograms/kg daily · subcutaneousAs given in this study (dog).

    Source sentences

    Summary
    Although there was a rise in the circulating levels of the gonadotropins and of testosterone following the early injections of agonist
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, early nafarelin injections raised testosterone.

    In plain wordsIn dogs, early nafarelin injections raised testosterone.

    Peptide
    Nafarelin
    Outcome
    IncreaseEarly testosterone response
    Study

    dogn: not reported in source

    adult male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 or 2.0 micrograms/kg daily · subcutaneousAs given in this study (dog).

    Source sentences

    Summary
    Although there was a rise in the circulating levels of the gonadotropins and of testosterone following the early injections of agonist
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, continued nafarelin reduced the acute LH response.

    In plain wordsIn dogs, continued nafarelin reduced the acute LH response.

    Peptide
    Nafarelin
    Outcome
    DecreaseAcute LH response
    Study

    dogn: not reported in source

    adult male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 or 2.0 micrograms/kg daily · subcutaneous · 44 daysAs given in this study (dog).

    Source sentences

    Summary
    continued treatment caused a marked decline in acute response and basal levels of both LH and testosterone and smaller decreases in the acute FSH response.
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, continued nafarelin reduced basal LH.

    In plain wordsIn dogs, continued nafarelin reduced basal LH.

    Peptide
    Nafarelin
    Outcome
    DecreaseBasal LH
    Study

    dogn: not reported in source

    adult male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 or 2.0 micrograms/kg daily · subcutaneous · 44 daysAs given in this study (dog).

    Source sentences

    Summary
    continued treatment caused a marked decline in acute response and basal levels of both LH and testosterone and smaller decreases in the acute FSH response.
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, continued nafarelin reduced the acute testosterone response.

    In plain wordsIn dogs, continued nafarelin reduced the acute testosterone response.

    Peptide
    Nafarelin
    Outcome
    DecreaseAcute testosterone response
    Study

    dogn: not reported in source

    adult male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 or 2.0 micrograms/kg daily · subcutaneous · 44 daysAs given in this study (dog).

    Source sentences

    Summary
    continued treatment caused a marked decline in acute response and basal levels of both LH and testosterone and smaller decreases in the acute FSH response.
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, continued nafarelin reduced basal testosterone.

    In plain wordsIn dogs, continued nafarelin reduced basal testosterone.

    Peptide
    Nafarelin
    Outcome
    DecreaseBasal testosterone
    Study

    dogn: not reported in source

    adult male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 or 2.0 micrograms/kg daily · subcutaneous · 44 daysAs given in this study (dog).

    Source sentences

    Summary
    continued treatment caused a marked decline in acute response and basal levels of both LH and testosterone and smaller decreases in the acute FSH response.
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, continued nafarelin produced smaller decreases in the acute FSH response.

    In plain wordsIn dogs, continued nafarelin reduced the acute FSH response.

    Peptide
    Nafarelin
    Outcome
    DecreaseAcute FSH response
    Study

    dogn: not reported in source

    adult male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 or 2.0 micrograms/kg daily · subcutaneous · 44 daysAs given in this study (dog).

    Source sentences

    Summary
    continued treatment caused a marked decline in acute response and basal levels of both LH and testosterone and smaller decreases in the acute FSH response.
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, nafarelin reduced testicular volume, sperm count, sperm motility, ejaculate volume and ejaculation duration.

    In plain wordsIn dogs, nafarelin reduced testicular volume, sperm count, sperm motility, ejaculate volume and ejaculation duration.

    Peptide
    Nafarelin
    Outcome
    DecreaseReproductive parameter decline
    Study

    dogn: not reported in source

    adult male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 or 2.0 micrograms/kg daily · subcutaneous · 44 daysAs given in this study (dog).

    Source sentences

    Summary
    The decline in LH and testosterone was accompanied by decreases in testicular volume, ejaculated sperm count, sperm motility, ejaculate volume, and duration of ejaculation.
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, reproductive parameters declined faster with nafarelin at 2.0 micrograms/kg than at 0.5 micrograms/kg.

    In plain wordsIn dogs, reproductive parameters declined faster with nafarelin at 2.0 micrograms/kg than at 0.5 micrograms/kg.

    Peptide
    Nafarelin
    Outcome
    IncreaseRate of reproductive parameter decline
    Study

    dogn: not reported in source

    adult male beagle dogs
    Comparator
    0.5 micrograms/kg daily nafarelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2.0 micrograms/kg daily · subcutaneous · 44 daysAs given in this study (dog).

    Source sentences

    Summary
    The decline in these parameters was more rapid at 2.0 micrograms/kg than at 0.5 micrograms/kg.
    2 context sentences
    Summary · context
    The decline in LH and testosterone was accompanied by decreases in testicular volume, ejaculated sperm count, sperm motility, ejaculate volume, and duration of ejaculation.
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, prostate weight after high-dose nafarelin was 36% of vehicle-treated control weight.

    In plain wordsIn dogs, prostate weight after high-dose nafarelin was 36% of vehicle-treated control weight.

    Peptide
    Nafarelin
    Outcome
    DecreaseProstate weight
    Study

    dogn: not reported in source

    adult male beagle dogs
    Comparator
    vehicle-treated controls
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2.0 micrograms/kg daily · subcutaneous · 44 daysAs given in this study (dog).

    Source sentences

    Summary
    At the end of treatment, prostate weights were 36% and 68% of vehicle-treated controls for high- and low-dose animals, respectively.
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, prostate weight after low-dose nafarelin was 68% of vehicle-treated control weight.

    In plain wordsIn dogs, prostate weight after low-dose nafarelin was 68% of vehicle-treated control weight.

    Peptide
    Nafarelin
    Outcome
    DecreaseProstate weight
    Study

    dogn: not reported in source

    adult male beagle dogs
    Comparator
    vehicle-treated controls
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 micrograms/kg daily · subcutaneous · 44 daysAs given in this study (dog).

    Source sentences

    Summary
    At the end of treatment, prostate weights were 36% and 68% of vehicle-treated controls for high- and low-dose animals, respectively.
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, spermatogenesis was absent in all nafarelin-treated animals.

    In plain wordsIn dogs, spermatogenesis was absent in all nafarelin-treated animals.

    Peptide
    Nafarelin
    Outcome
    DecreaseSpermatogenesis
    Study

    dogn: not reported in source

    adult male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 or 2.0 micrograms/kg daily · subcutaneous · 44 daysAs given in this study (dog).

    Source sentences

    Summary
    Spermatogenesis was absent in the testes of all agonist-treated animals.
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In male beagle dogs, nafarelin doses reached the same maximal effect but differed in the speed of response.

    In plain wordsIn dogs, nafarelin doses reached the same maximal effect but differed in the speed of response.

    Peptide
    Nafarelin
    Outcome
    No significant changeMaximal reproductive effect across doses
    Study

    dogn: not reported in source

    adult male beagle dogs
    Comparator
    other tested nafarelin dose
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 or 2.0 micrograms/kg daily · subcutaneous · 44 daysAs given in this study (dog).

    Source sentences

    Summary
    Over the dose range tested, the dose-response on all parameters was characterized by a slower evolution to the same maximal effect, rather than by a partial effect.
    1 context sentence
    Summary · context
    Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.